A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts
Public ClinicalTrials.gov record NCT02266745. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1, Open-Label, Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts
Study identification
- NCT ID
- NCT02266745
- Recruitment status
- Not listed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Promontory Therapeutics Inc.
- Industry
- Enrollment
- 109 participants
Conditions and interventions
Conditions
Interventions
- PT-112 Injection Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 2014
- Primary completion
- Jul 31, 2024
- Completion
- Mar 31, 2025
- Last update posted
- Apr 4, 2024
2014 – 2025
United States locations
- U.S. sites
- 17
- U.S. states
- 13
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona | Phoenix | Arizona | 85054 | — |
| Tucson | Tucson | Arizona | 85719 | — |
| Duarte | Duarte | California | 91010 | — |
| Colorado | Aurora | Colorado | 80045 | — |
| Jacksonville | Jacksonville | Florida | 32224 | — |
| Orlando | Orlando | Florida | 32806 | — |
| Indianapolis | Indianapolis | Indiana | 46202 | — |
| Boston | Boston | Massachusetts | 02215 | — |
| Minneapolis | Minneapolis | Minnesota | 55426 | — |
| Rochester | Rochester | Minnesota | 55905 | — |
| Omaha | Omaha | Nebraska | 68130 | — |
| Albuquerque | Albuquerque | New Mexico | 87190 | — |
| Brooklyn | Brooklyn | New York | 11215 | — |
| New York | New York | New York | 10065 | — |
| Durham | Durham | North Carolina | 27705 | — |
| University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Seattle | Seattle | Washington | 19024 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 8 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02266745, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 4, 2024 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02266745 live on ClinicalTrials.gov.